Alland, MD MSc DTM & H
Chief of Infectious Diseases, Professor
Alland obtained a B.A. in Psychology from Columbia University and an M.D.
from the Columbia College of Physicians and Surgeons. He performed his
Internship and Residency in Internal Medicine at The Columbia-Presbyterian
Hospital (Now the New York-Presbyterian Hospital), his Clinical Infectious
Disease fellowship at Montefiore Medical Center, and a Research Fellowship
at The Albert Einstein College of Medicine in the laboratory of Dr. Barry
Bloom. Dr. Alland also spent a year in The London School of Hygiene and
Tropical Medicine where he obtained an MSc. in Clinical Tropical Medicine
and a Diploma in Tropical Medicine and Hygiene. After serving on the Infectious
Disease Faculty of Montefiore Medical Center and the Albert Einstein College
of Medicine, Dr. Alland moved to New Jersey Medical School, first as a
member of the Infectious Disease faculty and then as Chief of the Division
of Infectious Disease.
Alland is a permanent member of the NIH ADDT (AIDS Discovery and Development
of Therapeutics) study section, has chaired several ad hoc study sections,
and reviewed grants for the WHO, Gates Foundation, and the Wellcome Trust.
Dr. Alland is the P.I. of a multi-center $2,500,000 grant from the NIH
to study the evolution of drug resistance in M. tuberculosis , a $2,000,000
grant from the NIH to study the evolution and phylogenetics of M. tuberculosis
, and a $3,000,000 grant from the NIH to develop novel biodefense diagnostics.
He has also been the principal investigator of a phase I Small Business
Technology Transfer (STTR) grant awarded to Cepheid Inc. to develop novel
methods to process clinical samples for PCR diagnostics. Dr. Alland was
a project leader in the development of the Northeast Regional Biodefense
Center, a multi-institution NIH grant to coordinate and promote biodefense
research, and sits on the Executive Committee of this program.
Alland has been awarded three patents based on his research: U.S. Patent
Number: 6,268,201: iniB, iniA and iniC genes of mycobacteria and methods
of use, U.S. Patent Number: 6,458,566: Method of identification of differentially
expressed mRNA and U.S. Patent Number: 6,461,817: Non-competitive co-amplification
methods. He has a forth patent pending based on recent work at UMDJ. In
2003, Dr. Alland was an invited speaker both the American Society of Microbiology
(ASM) and the American Thoracic Society (ATS) general meetings, and a
number of other international, national, and regional meetings. He has
recently published important articles on M.tuberculosis epidemiology (Murray
and Alland. Am. J. Epi . 2002. 155:565-571.), genomics (Fleischmann et
al., J. Bacteriol . 202. 184:5479-5490.), evolution (Alland et al., J.
Bacteriol . 2003. 85:3392-3399), and diagnostics (El-Hajj et al., J. Clin.
Microbiol. 2001. 39: 4131-4137).